Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Current Deferred Revenue for 8 consecutive years, with $6.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 3470.29% to $6.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.2 million, a 3470.29% increase, with the full-year FY2024 number at $3.0 million, down 75.43% from a year prior.
  • Current Deferred Revenue was $6.2 million for Q3 2025 at Precision Biosciences, up from $6.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $53.1 million in Q1 2021 to a low of $175000.0 in Q3 2024.
  • A 5-year average of $20.5 million and a median of $19.7 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: plummeted 99.0% in 2024, then skyrocketed 3470.29% in 2025.
  • Precision Biosciences' Current Deferred Revenue stood at $21.2 million in 2021, then soared by 117.44% to $46.2 million in 2022, then tumbled by 73.95% to $12.0 million in 2023, then tumbled by 75.43% to $3.0 million in 2024, then skyrocketed by 111.3% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Current Deferred Revenue are $6.2 million (Q3 2025), $6.0 million (Q2 2025), and $5.7 million (Q1 2025).